TORNTPHARM Q4 FY25 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,959 Cr
verified against source
Revenue YoY
8%
reported change
EBITDA
₹964 Cr
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Torrent Pharma delivered INR 2,959 crore revenue in Q4 FY25 (+8% YoY), with operating EBITDA of INR 964 crore at 32.6% margin (33.1% adjusted for one-time INR 17 crore impact from in-license product revaluation). India business grew 12% with 14% AIOCD growth, driven by chronic therapies outperforming IPM. Brazil faced BRL depreciation headwinds (11%) and channel de-stocking, but management targets 10-12% constant currency growth. U.S. grew 10% in constant currency but guidance pushed major launch traction to FY2027. Field force expansion to 6,800-6,900 by FY26 end from 6,400 currently underpins India growth ambitions. R&D spend expected to increase from ~5% towards 5.4% of revenue, focused on complex products in India, Brazil, and U.S. Net debt/EBITDA stands comfortable at 0.62x. Risk: Brazil channel de-stocking impact unclear for FY26; Semaglutide timing uncertain in Brazil despite INR 1 billion market potential.
Colored figures show movement against the previous available record.
Guidance to track
- Adding 400-500 MRs by FY26 year-end, primarily in chronic therapies, to improve territorial reach and new launch performance in expanded divisions.
- Expecting 10-12% constant currency growth in FY26, 2-3 percentage points ahead of estimated 9% market growth rate.
- R&D as percentage of sales expected to move from ~5% towards 5.4%, driven by complex products in India, Brazil, and U.S. ($5-10M per product vs $2M for oral solids).
- Expecting 7-8 launches including Eslicarbazepine (20%+ market share achieved on day one), Esomeprazole granules, and Diclofenac sachets. Meaningful growth impact delayed to FY27.
Risks flagged
- Q4 sales impacted by channel de-stocking due to expectation of low price increases for 2025-26. Full-year FY26 impact unclear as management could not quantify impact on EBITDA margins.
- Management explicitly refused to predict timing for Brazil launch, stating even filers in advanced markets like U.S. face approval delays. Market could see 5-10 filers but approvals not straightforward.
- Management had guided INR 120 crore quarterly run-rate recovery in Q4 but actual was only INR 75 crore. Catch-up expected in Q1-Q2 FY26 but quantum uncertain; suggests either lost contracts or timing mismatch.
- Despite pediatric exclusivity ending July 15, management indicated the generic opportunity is smaller than anticipated months ago due to delays. Multiple players expected simultaneously, pressuring market share potential.
Key quotes
- Usually, end of quarter four, I try and avoid giving any guidance. And then based on quarter one results, it's more clearer where we are heading for.
- The exact date is not certain, but it would most likely be in the first wave of any generic launch.
- I would expect not much impact this year, more impact next year, and even higher impact in the year afterwards.
Research modules